Venture capital fundraising by biopharmaceutical companies rose to $7.11bn in the fourth quarter of 2024, after falling to $6.46bn in Q3 from $7.95bn in Q2, according to data from Evaluate. But the year has shown a significant rebound. By the end of Q3, the 2024 fundraising total already exceeded the full-year 2023 total of $19.61bn, and with the Q4 data in hand, venture fundraising last year totaled $28.05bn, also beating the $27.27bn raised by drug developers in 2022.
With Q4 Data In, Biopharma VC Fundraising Reached Highest Total Since 2021
Fourth Quarter Continued Trend Of Uptick From 2023
Evaluate data from the fourth quarter of 2024 show another period of venture capital fundraising that beat each quarter of 2023, as $100m-plus mega-rounds surged.
